• 1
    Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J. Clin. Psychopharmacol. 2007; 27: 639661.
  • 2
    Johnsen E, Kroken RA, Abaza M, Olberg H, Jørgensen HA. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J. Clin. Psychopharmacol. 2008; 28: 686690.
  • 3
    Schoemaker H, Claustre Y, Fage D et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther. 1997; 280: 8397.
  • 4
    Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual ‘atypical’ antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 2002; 159: 180190.
  • 5
    Scatton B, Claustre Y, Cudennec A et al. Amisulpride: from animal pharmacology to therapeutic action. Int. Clin. Psychopharmacol. 1997; 12 (Suppl.): S29S36.
  • 6
    Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am. J. Psychiatry 1999; 156: 610616.
  • 7
    Martinot JL, Paillère-Martinot ML, Poirier MF, Dao-Castellana MH, Loc'h C, Mazière B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) 1996; 124: 154158.
  • 8
    Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 3141.
  • 9
    Lee BH, Kim YK. Resolution of amisulpride-associated amenorrhea by switching to aripiprazole. Psychiatry Invest. 2006; 3: 102106.
  • 10
    Kopecek M, Bares M, Svarc J. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol. Lett. 2004; 25: 419422.
  • 11
    Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog. Neuropsychopharmacol Biol. Psychiatry 2006; 30: 714717.
  • 12
    Paparrigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog. Neuropsychopharmacol Biol. Psychiatry 2007; 31: 9296.
  • 13
    Raj R, Sidhu BS. Hyperprolactinaemia with amisulpride. Indian J. Psychiatry 2008; 50: 5456.
  • 14
    Jaber M, Robinson S, Missale C, Caron M. Dopamine receptors and brain function. Neuropharmacology 1996; 35: 15031519.
  • 15
    Kapur S, Langlois X, Vinken P, Megens A, Coster RD, Andrews J. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 2002; 302: 11291134.
  • 16
    Bressan R, Erlandsson K, Spencer E, Ell P, Pilowsky L. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 2004; 175: 367373.
  • 17
    Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ 2003; 169: 575581.
  • 18
    Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J. Clin. Endocrinol. Metab. 2011; 96: 16331641.
  • 19
    Bahceci M, Sismanoglu A, Ulug U. Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. Gynecol. Endocrinol. 2010; 26: 505508.
  • 20
    Lee BH, Kim YK. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog. Neuropsychopharmacol Biol. Psychiatry 2006; 30: 658662.
  • 21
    Kleinberg DL, Davis JM, deCoster R, Van-Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 1999; 19: 5761.
  • 22
    American Psychiatric Association (ed.). Practice Guidelines for the Treatment of Patients with Schizophrenia. American Psychiatric Association, Washington, DC, 2004.
  • 23
    Eberhard J, Lindström E, Holstad M, Levander S. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr. Scand. 2007; 115: 268276.
  • 24
    Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol. Bull. 2002; 36: 143164.
  • 25
    Walters J, Jones I. Clinical questions and uncertainty – prolactin measurement in patients with schizophrenia and bipolar disorder. J. Psychopharmacol. 2008; 22: 8289.